Summary of Consolidated Financial Results for the Nine Months Ended December 31, 2025 (IFRS)

Listed Company Name:	Santen Pharmaceutical Co.,Ltd.
Exchanges Listed:	Tokyo (Prime Market)
Stock Code:	4536
URL:	https://www.santen.com/en
Representative:	Takeshi Ito, President and CEO
Contact:	Guillaume Sakuma, Global Head of Investor Relations (+81-6-7664-8621)
Start of Distribution of Dividends (Scheduled):	—
Preparation of Supplementary Material of the Financial Results:	Yes
Holding of Presentation of Financial Results:	Yes (for securities analysts and institutional investors)

(JPY millions)

1. Consolidated Performance for the Nine Months Ended December 31, 2025

(1) Operating Results

	Nine months ended December 31, 2024	Nine months ended December 31, 2025	Change
Revenue	222,773	210,763	(5.4%)
Core operating profit	43,655	34,793	(20.3%)
Operating profit	35,195	28,219	(19.8%)
Net profit for the period	27,348	21,998	(19.6%)
Net profit for the period attributable to owners of the company	27,465	21,816	(20.6%)
Total comprehensive income for the period	27,185	42,115	54.9%
Basic earnings per share (yen)	78.21	66.16	
Diluted earnings per share (yen)	77.98	66.05	

(2) Financial Position

	March 31, 2025	December 31, 2025
Total assets	409,277	401,161
Total equity	285,181	282,436
Total equity attributable to owners of the company	286,242	283,382
Total equity attributable to owners of the company ratio (%)	69.9	70.6
Equity per share attributable to owners of the company (yen)	839.20	881.45

2. Dividends

	Year to March 2025	Year to March 2026	(Forecasts) Year to March 2026
First quarter dividends per share (yen)	—	—	—
Second quarter dividends per share (yen)	17.00	19.00	—
Third quarter dividends per share (yen)	—	—	—
Year-end dividends per share (yen)	19.00	—	19.00
Annual dividends per share (yen)	36.00	—	38.00

(Note):

Revisions to the forecasts of dividends from the latest announcement: No

3. Consolidated Forecasts of Results for the Year Ending March 31, 2026

	Year to March 2026	Change
Revenue	294,000	(2.0%)
Core operating profit	54,000	(9.1%)
Operating profit	44,000	(6.1%)
Net profit for the year	33,500	(6.6%)
Net profit for the period attributable to owners of the company	34,000	(6.2%)
Basic earnings per share (yen)	102.66	(1.3%)

(Note):

Revisions to the forecasts of consolidated results from the latest announcement: No

1. Presentation of figures on a core basis has been revised from the fiscal year ended March 31, 2025.
2. Please refer to "1. Summary of Consolidated Results and Others (1) Summary of Consolidated Results for the Period" on page 3 of the attached material for details of the reconciliation from IFRS basis figures to core-based figures.
3. At a meeting of the Board of Directors on November 6, 2025, the Board resolved to cancel treasury shares; the shares were cancelled on November 28, 2025. While the share cancellation has been factored into the basic earnings per share forecasts for the year ending March 31, 2026, there are no changes to the forecast of consolidated results as disclosed on May 13, 2025. Please refer to “2. Condensed Interim Consolidated Financial Statements and Major Notes (5) Notes to Condensed Interim Consolidated Financial Statements” on page 14 for details of the cancellation.

*Notes

(1) Significant changes in scope of consolidation during the period: No

(2) Changes in accounting policies and accounting estimates

(i) Changes in accounting policies required by IFRS : No
(ii) Changes in accounting policies other than (i) : No
(iii) Changes in accounting estimates : No

(3) Number of ordinary shares issued

(i) Number of shares outstanding at the end of period (including treasury shares)

December 31, 2025	322,273,954 shares
March 31, 2025	342,055,554 shares

(ii) Number of treasury shares at the end of period

December 31, 2025	602,370 shares
March 31, 2025	691,515 shares

(iii) Average number of outstanding shares

The third quarter ended December 31, 2025	329,628,807 shares
The third quarter ended December 31, 2024	351,070,525 shares

(Note):
The number of treasury shares at the end of the period includes shares (59,329 shares for the fiscal year ended March 31, 2025 and 27,968 shares as of December 31, 2025 of the fiscal year ending March 31, 2026) owned in trust for the stock compensation system. Such shares are included in the treasury shares which are excluded from the calculation of the average number of shares outstanding during the period.

*Audit by a certified public accountant or auditing firm for the quarterly consolidated financial statements: No

*Explanations and other special notes concerning the appropriate use of business performance forecasts

(Notes on forward-looking statements)
The earnings forecasts and other forward-looking statements contained in this report are based on information currently available to the Company and on certain assumptions deemed to be reasonable by the Company. Actual results may differ from these forecasts due to various factors.

(Method of obtaining supplementary explanatory materials for financial results and results presentation contents)
The Santen Group plans to hold a briefing on the results for securities analysts and institutional investors on Thursday, February 5, 2026. The materials used in this briefing will be posted on our website.

Accompanying Materials – Contents

1. Summary of Consolidated Results and Others

(1) Summary of Consolidated Results for the Period

(I) Consolidated Results

(JPY billions)

	Nine months ended December 31, 2024	Nine months ended December 31, 2025	Year-on-year change
Revenue	222.8	210.8	(5.4%)
Core operating profit[*1]	43.7	34.8	(20.3%)
Operating profit	35.2	28.2	(19.8%)
Net profit for the period	27.3	22.0	(19.6%)
Net profit for the period attributable to owners of the company	27.5	21.8	(20.6%)
EBITDA[*2]	50.6	42.0	(17.0%)

Although consolidated revenue and each level of profit for the nine months ended December 31, 2025 decreased, progress toward the consolidated forecasts of results for the fiscal year ending March 31, 2026, which were disclosed on May 13, 2025, was steady and in line with projections.

[Revenue]

Revenue in the nine months ended December 31, 2025 decreased by 5.4% year-on-year to ¥210.8 billion. This was mainly due to the focus on expanding sales of new and mainstay products despite the impact of NHI price revisions and adjustments to channel inventory levels.

◇ Japan

Revenue in the nine months ended December 31, 2025 decreased by 12.4% year-on-year to ¥104.8 billion. NHI price revisions at the high end of the 1% level, market expansion re-pricing of mainstay products, the absence of the strong performance of *Alesion* products at the end of the previous fiscal year and impact of co-pay hikes on certain long-listed products (the *"sentei-ryoyo*" system that came into effect in October 2024) were partially offset by the focus on growing mainstay products such as *RYJUSEA Mini* which was launched in April 2025, *EYLEA* kit for IVT inj. 114.3mg/mL which was launched in May 2025 and *Alesion* eyelid cream. Within total Japan revenue, revenue from OTC (excluding China and Asia) increased by 10.3% year-on-year to ¥9.0 billion.

◇ China

Revenue excluding FX impact in the nine months ended December 31, 2025 was largely in line with the previous fiscal year (-0.7% year-on-year) despite the impact of adjustments to channel inventory levels. On a JPY basis, revenue decreased by 2.8% year-on-year to ¥23.1 billion. Starting this fiscal year, Hong Kong is included in the China segment rather than the Asia segment. For reference, the calculation of the year-on-year growth rate takes into account this change.

◇ Asia (excluding China)

On a JPY basis, revenue in the nine months ended December 31, 2025 increased by 9.3% year-on-year (+12.2% excluding FX impact) to ¥23.7 billion. This was due to the steady growth of glaucoma and dry eye products sold in South Korea and Southeast Asia, and the contribution of an exclusive promotion and distribution agreement for VEGF inhibitors, *Beovu* and *Lucentis*, in South Korea.

◇ EMEA[*3]

On a JPY basis, revenue in the nine months ended December 31, 2025 increased by 2.8% year-on-year (-1.9% excluding FX impact) to ¥58.2 billion. This was mainly due to the focus on building leadership positions in the glaucoma and dry eye fields.

[Core operating profit]

Gross profit in the nine months ended December 31, 2025 decreased by 5.7 % year-on-year to ¥117.9 billion.
SG&A expenses in the nine months ended December 31, 2025 increased by 0.1% year-on-year (-1.0% excluding FX impact) to ¥64.8 billion.
R&D expenses in the nine months ended December 31, 2025 increased by 9.5% year-on-year (+9.2% excluding FX impact) to ¥18.4 billion.

As a result, operating profit on a core basis in the nine months ended December 31, 2025 decreased by 20.3% year-on-year (-20.1% excluding FX impact) to ¥34.8 billion.

[Operating profit]

Amortization on intangible assets associated with products in the nine months ended December 31, 2025 increased by 0.2% year-on-year (-0.5% excluding FX impact) to ¥6.7 billion. This was mainly due to the amortization on intangible assets associated with products acquired from Merck & Co., Inc. (U.S.) in 2014, *PRESERFLO MicroShunt* which was launched in Europe in 2019, *Ikervis* which was launched in Europe in 2015, and *Rocklatan / Roclanda* which Santen began selling in Europe in 2023 and Asia in 2024.

Other income amounted to ¥0.3 billion.
Other expenses amounted to ¥0.2 billion.

As a result, operating profit on an IFRS basis in the nine months ended December 31, 2025 decreased by 19.8% year-on-year (-19.5% excluding FX impact) to ¥28.2 billion.

[Net profit for the period]

Finance income amounted to ¥1.3 billion.
Finance expenses amounted to ¥1.5 billion.
Income tax expenses amounted to ¥6.1 billion, down ¥1.9 billion year-on-year. This was mainly due to the decrease of profit before tax as a result of the aforementioned decrease in operating profit on an IFRS basis.

As a result, net profit for the period ended December 31, 2025 decreased by 19.6% year-on-year to ¥22.0 billion.

[Net profit for the period attributable to owners of the company]

Net profit for the period attributable to owners of the company in the nine months ended December 31, 2025 decreased by 20.6% year-on-year to ¥21.8 billion. The ratio to revenue was 10.4%.

*1 With the adoption of IFRS in the fiscal year ended March 31, 2015, the Santen Group discloses financial information on a core basis, which is calculated by excluding certain income and expense items from the IFRS basis, as an indicator of ordinary performance. The core basis is calculated by deducting the following income and expense items from IFRS results.

- Amortization on intangible assets associated with products
- Other income
- Other expenses
- Expenses related to acquisitions of companies

*2 EBITDA is calculated as follows: EBITDA = (Operating profit) - (Other income) + (Other expenses) + (Depreciation and amortization)

*3 Europe, Middle East and Africa.

(II) Research & Development Activities

<Glaucoma and ocular hypertension area>

STN1011101 (DE-111A, generic name: tafluprost / timolol maleate) is a fixed dose combination drug of a prostaglandin F_{2a} derivative and a beta-adrenergic receptor blocker. The Company launched the product in China in August 2025.

STN1011702 (generic name: omidenepag isopropyl) is an EP2 receptor agonist. Phase 3 trial has been under way in China since November 2024.

STN1012600 (DE-126, generic name: sepetaprost) is an agonist that activates both FP and EP3 receptors. An additional Phase 2 trial was completed in the U.S. in December 2021. The Company launched the product in Japan in October 2025. Phase 2 trial (exploratory study) was completed in Europe.

STN1013001 (DE-130A, generic name: latanoprost) is an ophthalmic emulsion of a prostaglandin $F_{2\alpha}$ derivative. The Company filed for marketing approval in Asia in November 2024. The Company launched the product in European countries including Spain in August 2024.

STN1013900 (AR-13324, generic name: netarsudil mesylate) is a ROCK inhibitor. The Company filed as a ROCK/NET inhibitor for manufacturing and marketing approval in Japan in July 2025. Marketing approval has been received in Europe, and the Company has launched the product in Sweden and other countries from February 2023 onward. The Company has successively received marketing approval in Asian countries and launched in South Korea in November 2024.

STN1014000 (PG-324, generic name: netarsudil mesylate / latanoprost) is a fixed dose combination drug of a ROCK inhibitor and a prostaglandin $F_{2\alpha}$ derivative. Marketing approval has been received in Europe, and the Company has launched the product in Germany and other countries from January 2023 onward. The Company has successively received marketing approval in Asian countries and launched in Singapore in March 2025.

STN1014003 (generic name: netarsudil mesylate / latanoprost) is a fixed dose combination drug of a ROCK inhibitor and a prostaglandin $F_{2\alpha}$ derivative. Phase 3 trial was started in Japan in February 2025.

<Keratoconjunctival disease area including dry eye>

STN1007603 (DE-076C, generic name: ciclosporin) for vernal keratoconjunctivitis has been approved and launched in Europe and Asia. The Company launched the product in China in December 2025.

STN1014100 (generic name: olodaterol hydrochloride) is for the treatment of dry eye. Phase 2b trial was started in Japan in May 2025.

STN1010904* (generic name: sirolimus) is for the treatment of Fuchs endothelial corneal dystrophy. The Company has executed a joint development agreement with ActualEyes Inc. Phase 2a trial has been under way in the U.S., France and India since May 2022. (*The development code (STN1010904) is due to be assigned to the product when Santen obtains an exclusive license upon completion of Phase 2 clinical trial.)

STN1010905 (generic name: sirolimus) is for the treatment of meibomian gland dysfunction. An additional Phase 2a trial has been under way in Japan since June 2024.

STN1011402 (generic name: epinastine hydrochloride) is an eyelid cream for the treatment of allergic conjunctivitis. The Company launched the product in Japan in May 2024. Phase 3 trial was started in China in January 2026. The Company filed for marketing approval in Asia in December 2025.

STN1011403 (generic name: epinastine hydrochloride) is a high dose formulation to instill twice a day for the treatment of allergic conjunctivitis. The Company filed for marketing approval in China in March 2025.

STN1014200 (CBT-001, generic name: nintedanib) is for the treatment of pterygium. Phase 2b trial was started in Japan in November 2025.

<Refractive disorder>

STN1012700 (DE-127, generic name: atropine sulfate) is for the treatment of myopia in children. The Company launched the product in Japan in April 2025. Phase 2/3 trial has been under way in China since June 2022. The Company filed for marketing approval in Asia in July 2025.

STN1012701 (SYD-101, generic name: atropine sulfate) is for the treatment of myopia in children. In Europe, the Company launched the product in Germany in July 2025.

<Retinal diseases area>

STN1014300 (RC28-E, generic name: eflimrufusp alfa) is for the treatment of diabetic macular edema. RemeGen Co., Ltd. (China), the licensor, filed for marketing approval in China in September 2025.

STN1014301 (RC28-E, generic name: eflimrufusp alfa) is for the treatment of wet age-related macular degeneration. RemeGen Co., Ltd. (China), the licensor, is conducting Phase 3 trial in China.

<Others>

STN1013800 (generic name: oxymetazoline hydrochloride) is for the treatment of ptosis. The Company received manufacturing and marketing approval in Japan in December 2025. Phase 3 trial has been under way in Europe since December 2024. Phase 3 trial has been under way in China since October 2024.

※ The numbering method for development codes has changed. Both existing development codes (DE-XXX) and new development codes (STNXXXXXXX) are shown. AR-13324/PG-324, SYD-101, RC28-E and CBT-001 are the development codes of Alcon Inc. (Switzerland), Sydnexis Inc. (U.S.), RemeGen Co., Ltd. (China) and Cloudbreak Pharma Inc. (U.S.) respectively.

(2) Summary of Financial Position for the Period

(I) Assets, equity and liabilities

Total assets at the end of December 31, 2025 amounted to ¥401.2 billion, a decrease of ¥8.1 billion from the end of the previous fiscal year ended March 31, 2025. Despite an increase of product inventories in connection with the resumption of shipments for *Diquas LX,* there were decreases in working capital associated with the liquidation of trade receivables, and a decrease in cash and others.

Equity amounted to ¥282.4 billion, a decrease of ¥2.7 billion from the end of the previous fiscal year ended March 31, 2025. This was due to a decrease in retained earnings caused by the cancellation of treasury shares despite an increase in other components of equity.

Liabilities amounted to ¥118.7 billion, a decrease of ¥5.4 billion from the end of the previous fiscal year ended March 31, 2025. Despite an increase in financial liabilities, there were decreases in trade and other payables, and other current liabilities.

As a result, the ratio of equity attributable to owners of the company to total assets increased by 0.7%-points from the end of the previous fiscal year ended March 31, 2025 to 70.6%.

The Santen Group views ROE (equity attributable to owners of the company profit ratio) as its most important management metric. The Company aims to maximize shareholder value by focusing on both maximizing cash flow and lowering the cost of capital. While the inflow of cash from operating activities is considered the basic source of cash, the Company is also implementing measures to maximize cash-generating capability by improving working capital efficiency through the management of the cash conversion cycle. As part of this effort, the Company is liquidating trade receivables to improve ROIC (return on invested capital).

(II) Cash Flows

Cash flows from operating activities amounted to an inflow of ¥22.5 billion (inflow of ¥42.0 billion in the nine months ended December 31, 2024). This was mainly due to the net profit for the period of ¥22.0 billion, ¥13.8 billion in depreciation and amortization, a decrease of ¥6.9 billion in trade and other payables and a ¥6.4 billion corporate tax payment.

Cash flows from investing activities amounted to an outflow of ¥11.6 billion (outflow of ¥7.2 billion in the nine months ended December 31, 2024). This was mainly due to payments for the acquisition of property, plant and equipment and intangible assets amounting to ¥5.0 billion and ¥6.8 billion respectively.

Cash flows from financing activities amounted to an outflow of ¥47.8 billion (outflow of ¥52.4 billion in the nine months ended December 31, 2024). This was mainly due to share repurchases and cash dividends paid of ¥32.8 billion and ¥12.6 billion respectively.

As a result, cash and cash equivalents at the end of December 31, 2025 decreased by ¥31.5 billion from the end of the fiscal year ended March 31, 2025 to ¥61.5 billion.

(3) Information about Forecasts of Consolidated Financial Results and Other Forward-Looking Statements

The results for the period of the fiscal year under review have broadly remained in line with plan. No changes have been made to the forecasts of consolidated financial results for the year ending March 31, 2026 announced on May 13, 2025.

2. Condensed Interim Consolidated Financial Statements and Major Notes

(1) Condensed Interim Consolidated Statements of Income and Comprehensive Income

IFRS (JPY millions)

	Nine months ended December 31, 2024	Nine months ended December 31, 2025
Revenue	**222,773**	**210,763**
Cost of sales	(97,642)	(92,814)
Gross profit	**125,130**	**117,949**
Selling, general and administrative expenses	(64,702)	(64,784)
Research and development expenses	(16,773)	(18,372)
Amortization on intangible assets associated with products	(6,638)	(6,651)
Other income	384	312
Other expenses	(2,206)	(236)
Operating profit	**35,195**	**28,219**
Finance income	1,429	1,339
Finance expenses	(1,316)	(1,482)
Profit before tax	**35,309**	**28,076**
Income tax expenses	(7,961)	(6,077)
Net profit for the period	**27,348**	**21,998**
Other comprehensive income		
Items that will not be reclassified subsequently to profit or loss		
Net gain on financial assets measured at fair value through other comprehensive income	(2,221)	1,570
Items that may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	1,928	18,546
Cash flow hedges	15	—
Share of other comprehensive income of investments accounted for using equity method	115	—
Other comprehensive income	**(163)**	**20,116**
Total comprehensive income	**27,185**	**42,115**
Net profit attributable to		
Owners of the company	27,465	21,816
Non-controlling interests	(117)	183
Net profit for the period	**27,348**	**21,998**
Total comprehensive income attributable to		
Owners of the company	27,318	41,999
Non-controlling interests	(132)	115
Total comprehensive income	**27,185**	**42,115**
Earnings per share		
Basic earnings per share (yen)	78.21	66.16
Diluted earnings per share (yen)	77.98	66.05

Core basis (JPY millions)

	Nine months ended December 31, 2024	Nine months ended December 31, 2025
Core operating profit	43,655	34,793

(2) Condensed Interim Consolidated Statements of Financial Position

Assets (JPY millions)

	As of March 31, 2025	As of December 31, 2025
Non-current assets		
Property, plant and equipment	72,954	77,054
Intangible assets	75,467	77,477
Financial assets	16,177	23,130
Retirement benefit assets	7,861	7,470
Deferred tax assets	10,017	10,176
Other non-current assets	2,501	2,746
Total non-current assets	**184,978**	**198,054**
Current assets		
Inventories	51,590	60,071
Trade and other receivables	71,759	68,620
Other financial assets	997	4,275
Income taxes receivable	324	730
Other current assets	6,633	7,866
Cash and cash equivalents	92,997	61,544
Total current assets	**224,300**	**203,107**
Total assets	**409,277**	**401,161**

Equity and liabilities (JPY millions)

	As of March 31,2025	As of December 31, 2025
Equity		
Equity attributable to owners of the company		
Share capital	8,806	8,819
Capital surplus	9,797	9,364
Treasury shares	(1,161)	(978)
Retained earnings	228,291	205,635
Other components of equity	40,509	60,542
Total equity attributable to owners of the company	**286,242**	**283,382**
Non-controlling interests	**(1,061)**	**(946)**
Total equity	**285,181**	**282,436**
Liabilities		
Non-current liabilities		
Financial liabilities	30,940	36,146
Net defined benefit liabilities	1,221	1,433
Income taxes payable	122	—
Provisions	670	716
Deferred tax liabilities	2,606	2,983
Other non-current liabilities	1,701	1,781
Total non-current liabilities	**37,260**	**43,060**
Current liabilities		
Trade and other payables	38,989	32,854
Other financial liabilities	25,573	24,036
Income taxes payable	2,239	2,156
Provisions	2,087	1,412
Other current liabilities	17,949	15,206
Total current liabilities	**86,837**	**75,665**
Total liabilities	**124,096**	**118,725**
Total equity and liabilities	**409,277**	**401,161**

(3) Condensed Interim Consolidated Statements of Changes in Equity

Nine months ended December 31, 2024 (JPY millions)

	Share capital	Capital surplus	Treasury shares	Retained earnings	Other components of equity		
					Remeasurements of defined benefit plans	Net gain or loss on financial assets measured at fair value through other comprehensive income	Exchange differences on translation of foreign operations
Balance at April 1, 2024	8,777	9,854	(1,018)	240,029	—	5,481	40,306
Comprehensive income							
Net profit for the period				27,465			
Other comprehensive income						(2,221)	1,944
Total comprehensive income	—	—	—	27,465	—	(2,221)	1,944
Transactions with owners							
Issuance of new shares	19	19					
Repurchase of treasury shares		(46)	(37,836)				
Disposal of treasury shares		8	875				
Cancellation of treasury shares		(28,400)	28,400				
Transfer to capital surplus from retained earnings		28,392		(28,392)			
Dividends				(12,112)			
Share-based payments		(231)					
Other				384		(384)	
Total transactions with owners	19	(258)	(8,562)	(40,120)	—	(384)	—
Balance at December 31, 2024	8,797	9,596	(9,580)	227,374	—	2,876	42,249

(JPY millions)

	Other components of equity				Total equity attributable to owners of the company	Non-controlling interests	Total equity
	Cash flow hedges	Share of other comprehensive income of investments accounted for using equity method	Share acquisition rights	Total			
Balance at April 1, 2024	(20)	2,464	181	48,411	306,055	(685)	305,369
Comprehensive income							
Net profit for the period				—	27,465	(117)	27,348
Other comprehensive income	15	115		(147)	(147)	(15)	(163)
Total comprehensive income	15	115	—	(147)	27,318	(132)	27,185
Transactions with owners							
Issuance of new shares			(38)	(38)	0		0
Repurchase of treasury shares				—	(37,883)		(37,883)
Disposal of treasury shares				—	882		882
Cancellation of treasury shares				—	—		—
Transfer to capital surplus from retained earnings				—	—		—
Dividends				—	(12,112)		(12,112)
Share-based payments				—	(231)		(231)
Other				(384)	—		—
Total transactions with owners	—	—	(38)	(422)	(49,344)	—	(49,344)
Balance at December 31, 2024	(5)	2,580	142	47,842	284,028	(817)	283,211

Nine months ended December 31, 2025 (JPY millions)

	Share capital	Capital surplus	Treasury shares	Retained earnings	Other components of equity		
					Remeasurements of defined benefit plans	Net gain or loss on financial assets measured at fair value through other comprehensive income	Exchange differences on translation of foreign operations
Balance at April 1, 2025	8,806	9,797	(1,161)	228,291	—	2,616	37,629
Comprehensive income							
Net profit for the period				21,816			
Other comprehensive income						1,570	18,613
Total comprehensive income	—	—	—	21,816	—	1,570	18,613
Transactions with owners							
Issuance of new shares	14	14					
Repurchase of treasury shares		(22)	(32,774)				
Disposal of treasury shares		1	1,019				
Cancellation of treasury shares		(31,937)	31,937				
Transfer to capital surplus from retained earnings		31,936		(31,936)			
Dividends				(12,659)			
Share-based payments		(424)					
Other				124		(124)	
Total transactions with owners	14	(433)	182	(44,472)	—	(124)	—
Balance at December 31, 2025	8,819	9,364	(978)	205,635	—	4,063	56,242

(JPY millions)

	Other components of equity				Total equity attributable to owners of the company	Non-controlling interests	Total equity
	Cash flow hedges	Share of other comprehensive income of investments accounted for using equity method	Share acquisition rights	Total			
Balance at April 1, 2025	—	140	124	40,509	286,242	(1,061)	285,181
Comprehensive income							
Net profit for the period				—	21,816	183	21,998
Other comprehensive income				20,184	20,184	(68)	20,116
Total comprehensive income	—	—	—	20,184	41,999	115	42,115
Transactions with owners							
Issuance of new shares			(27)	(27)	0		0
Repurchase of treasury shares				—	(32,797)		(32,797)
Disposal of treasury shares				—	1,021		1,021
Cancellation of treasury shares				—	—		—
Transfer to capital surplus from retained earnings				—	—		—
Dividends				—	(12,659)		(12,659)
Share-based payments				—	(424)		(424)
Other				(124)	—		—
Total transactions with owners	—	—	(27)	(151)	(44,860)	—	(44,860)
Balance at December 31, 2025	—	140	97	60,542	283,382	(946)	282,436

(4) Condensed Interim Consolidated Statements of Cash Flows

(JPY millions)

	Nine months ended December 31, 2024	Nine months ended December 31, 2025
I. Cash flows from operating activities:		
Net profit for the period	27,348	21,998
Depreciation and amortization	13,549	13,804
Impairment losses	200	—
Interest income, dividend income and interest expenses (increase)	(459)	(255)
Income tax expenses	7,961	6,077
Decrease (increase) in trade and other receivables	21,862	5,872
Decrease (increase) in inventories	(6,267)	(5,376)
Increase (decrease) in trade and other payables	(7,793)	(6,949)
Increase (decrease) in provisions and net defined benefit liabilities	116	(310)
Decrease (increase) in other current assets	(104)	(846)
Increase (decrease) in accounts payable - bonuses	(2,762)	(1,054)
Increase (decrease) in accounts payable - other	(6,591)	(3,298)
Increase (decrease) in deposits received	2,679	(2,175)
Other	2,623	1,315
Subtotal	52,363	28,803
Interest received	748	602
Dividends received	413	351
Interest paid	(773)	(843)
Income tax paid	(10,714)	(6,392)
Net cash flows from (used in) operating activities	**42,038**	**22,521**
II. Cash flows from investing activities:		
Payments for acquisition of investments	(2)	(105)
Proceeds from sales of investments	1,294	244
Payments for acquisition of property, plant and equipment	(5,735)	(4,953)
Payments for acquisition of intangible assets	(2,520)	(6,765)
Other	(285)	(37)
Net cash flows from (used in) investing activities	**(7,247)**	**(11,617)**
III. Cash flows from financing activities:		
Repayments of long-term borrowings	(159)	—
Purchase of treasury shares	(37,883)	(32,795)
Dividends paid	(12,044)	(12,574)
Repayments of lease obligation	(2,361)	(2,467)
Other	0	2
Net cash flows from (used in) financing activities	**(52,446)**	**(47,834)**
IV. Net increase (decrease) in cash and cash equivalents	**(17,656)**	**(36,930)**
V. Cash and cash equivalents at the beginning of period	**94,582**	**92,997**
VI. Effect of exchange rate changes on cash and cash equivalents	**925**	**5,477**
VII. Cash and cash equivalents at the end of period	**77,851**	**61,544**

(5) Notes to Condensed Interim Consolidated Financial Statements

(Going Concern Assumption)

Not applicable.

(Segment Information and Others)

Segment information is omitted because the Santen Group is a single segment.

(Statement of Significant Changes in Shareholders' Equity)

Nine months ended December 31, 2024

(Repurchase of own shares)

At a meeting of the Board of Directors on May 9, 2024, the Board resolved to repurchase its own shares in accordance with Article 156 of the Companies Act (Japan), as applied pursuant to Article 165, paragraph 3. Santen repurchased a total of 16,985,400 of its own shares for a total value of 28,645 million yen during the period between May 10, 2024 to November 6, 2024. This repurchase was completed as of November 6, 2024 (execution date basis).

The Company also resolved to repurchase its own shares in accordance with Article 156 of the Companies Act (Japan), as applied pursuant to Article 165, paragraph 3 at the meeting of the Board of Directors on November 7, 2024. Santen repurchased a total of 5,000,000 of its own shares for a total value of 8,490 million yen during the period between November 8, 2024 to December 12, 2024 and the repurchase was completed as of December 12, 2024 (execution date basis).

(I) Reasons for repurchase of own shares

This repurchase is implemented in accordance with the capital allocation policy in the medium-term management plan (FY2023-2025) dated April 13, 2023, to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment.

(II) Details of repurchase

(1) Class of shares to be acquired	Common shares
(2) Total number of shares to be acquired	5,000,000 shares (maximum) *Representing 1.4% of the total number of shares outstanding (excluding treasury shares)
(3) Total amount of acquisition	10.0 billion yen (maximum)
(4) Period of acquisition	November 8, 2024 to March 21, 2025
(5) Method of acquisition	Open-market repurchase by discretionary trading method

(Cancellation of Treasury Shares)

At a meeting of the Board of Directors on November 7, 2024, the Board resolved to cancel treasury shares in accordance with Article 178 of the Companies Act (Japan). The Company completed this cancellation on November 29, 2024. The shares the Company cancelled are the treasury shares Santen repurchased based on the resolution at the Board of Directors meeting held on May 9, 2024.

(1) Class of shares to be canceled	Common shares
(2) Total number of shares to be canceled	16,985,400 shares (The ratio against total number of the outstanding shares before the Cancellation: 4.7%)
(3) Completion date of cancellation	November 29, 2024

Nine months ended December 31, 2025

(Repurchase of own shares)

At a meeting of the Board of Directors on May 13, 2025, the Board resolved to repurchase its own shares in accordance with Article 156 of the Companies Act (Japan), as applied pursuant to Article 165, paragraph 3. Santen repurchased a total of 19,800,000 of its own shares for a total value of 31,896 million yen during the period between May 22, 2025 to November 5, 2025.

(Cancellation of Treasury Shares)

At a meeting of the Board of Directors on November 6, 2025, the Board resolved to cancel treasury shares in accordance with Article 178 of the Companies Act (Japan). The Company completed this cancellation on November 28, 2025. The shares the Company cancelled are the treasury shares Santen repurchased based on the resolution at the Board of Directors meeting held on May 13, 2025.

(1) Class of shares to be canceled	Common shares
(2) Total number of shares to be canceled	19,800,000 shares (The ratio against total number of the outstanding shares before the Cancellation: 5.8%)
(3) Completion date of cancellation	November 28, 2025

(Significant Subsequent Events)

Not applicable.

3. Consolidated Reference
(1) Revenue of Major Products

(JPY millions)

Bran0	Region	Year ended March 31, 2025		Year ending March 31, 2026				
		Nine months ended December 31, 2024 Actual	Year ended March 31, 2025 Actual	Nine months ended December 31, 2025 Actual	Changes from the same period of previous year	Forecast for the fiscal year ending March 31, 2026 (Announced on February 5)	Changes from the same period of previous year	Forecast for the fiscal year ending March 31, 2026 (Announced on May 13)
Glaucoma and ocular hypertension								
Cosopt	Total	20,437	26,799	20,549	0.5%	25,124	(6.2%)	24,850
	Japan	2,117	2,530	1,336	(36.9%)	1,635	(35.4%)	1,361
	Asia	5,237	6,919	5,277	0.8%	7,014	1.4%	7,014
	EMEA	13,021	17,252	13,853	6.4%	16,379	(5.1%)	16,379
Tapros	Total	12,926	16,461	11,876	(8.1%)	15,853	(3.7%)	15,386
	Japan	2,751	3,316	1,824	(33.7%)	2,759	(16.8%)	2,759
	China	1,793	2,472	1,845	2.9%	2,332	(5.7%)	1,864
	Asia	1,761	2,337	1,796	2.0%	2,704	15.7%	2,704
	EMEA	6,621	8,336	6,412	(3.2%)	8,059	(3.3%)	8,059
Tapcom	Total	7,355	9,661	7,029	(4.4%)	9,712	0.5%	9,712
	Japan	1,278	1,562	856	(33.0%)	1,201	(23.1%)	1,201
	China	72	82	57	(21.0%)	193	134.6%	193
	Asia	1,099	1,499	1,214	10.5%	1,580	5.4%	1,580
	EMEA	4,906	6,519	4,901	(0.1%)	6,738	3.4%	6,738
Eybelis	Total	4,063	5,291	4,297	5.8%	5,504	4.0%	5,504
	Japan	3,582	4,625	3,656	2.0%	4,612	(0.3%)	4,612
	Asia	478	662	637	33.4%	885	33.7%	885
Catiolanze	Total	53	141	632	–	1,109	689.0%	1,109
	EMEA	53	141	632	–	1,109	689.0%	1,109
Rocklatan/Roclanda	Total	613	911	1,000	63.1%	1,798	97.3%	1,798
	Asia	2	4	19	–	23	549.5%	23
	EMEA	611	908	981	60.5%	1,775	95.5%	1,775
Dry eye								
Diquas	Total	8,563	11,134	7,899	(7.8%)	10,233	(8.1%)	9,493
	Japan	4,866	6,501	4,901	0.7%	5,588	(14.0%)	4,848
	China	2,128	2,504	1,332	(37.4%)	2,072	(17.2%)	2,072
	Asia	1,569	2,130	1,667	6.2%	2,573	20.8%	2,573
Diquas LX	Total	–	–	965	–	4,131	–	4,131
	Japan	–	–	965	–	4,131	–	4,131
Hyalein	Total	13,306	16,896	12,516	(5.9%)	15,886	(6.0%)	15,886
	Japan	3,715	4,690	2,795	(24.8%)	3,368	(28.2%)	3,368
	China	6,759	8,312	6,546	(3.2%)	8,407	1.1%	8,407
	Asia	2,831	3,893	3,175	12.1%	4,111	5.6%	4,111
Ikervis	Total	8,293	11,290	9,572	15.4%	12,132	7.5%	12,132
	Asia	1,443	1,947	1,554	7.7%	2,215	13.7%	2,215
	EMEA	6,758	9,149	7,972	18.0%	9,777	6.9%	9,777
Cationorm	Total	3,460	4,324	2,905	(16.1%)	4,490	3.8%	4,490
	China	282	283	189	(33.0%)	679	140.4%	679
	Asia	545	709	650	19.3%	808	14.0%	808
	EMEA	2,380	3,080	1,990	(16.4%)	3,003	(2.5%)	3,003
Allergy								
Alesion (Including Alesion LX, Alesion eyelid cream, Epinastine hydrochloride and Epinastine hydrochloride LX)	Total	15,847	31,702	9,998	(36.9%)	26,966	(14.9%)	26,861
	Japan	15,643	31,393	9,659	(38.3%)	26,504	(15.6%)	26,504
	Asia	204	309	339	66.1%	462	49.4%	357
Verkazia	Total	1,472	1,821	1,831	24.4%	2,267	24.5%	2,267
	China	–	–	10	–	145	–	145
	EMEA	1,450	1,799	1,821	25.6%	2,121	17.9%	2,121
Intravitreal VEGF inhibitor								
EYLEA (Including EYLEA 8mg, EYLEA 8mg intraocular injection kit)	Total	60,308	78,052	53,032	(12.1%)	71,575	(8.3%)	71,575
	Japan	60,308	78,052	53,032	(12.1%)	71,575	(8.3%)	71,575
Bacterial conjunctivitis								
Cravit	Total	11,027	13,641	10,765	(2.4%)	13,393	(1.8%)	13,393
	Japan	572	679	364	(36.3%)	420	(38.1%)	420
	China	7,118	8,492	7,083	(0.5%)	8,287	(2.4%)	8,287
	Asia	2,134	2,895	2,191	2.7%	3,086	6.6%	3,086
	EMEA	1,202	1,576	1,126	(6.3%)	1,600	1.5%	1,600
Slowing myopia progression								
Ryjusea/Ryjunea	Total	–	–	1,038	–	1,873	–	1,606
	Japan	–	–	746	–	1,413	–	1,413
	EMEA	–	–	292	–	460	–	193
Medical devices								
PRESERFLO MicroShunt	Total	4,213	6,053	5,793	37.5%	7,696	27.1%	7,007
	Japan	1,131	1,680	1,680	48.6%	2,435	45.0%	1,746
	Asia	77	120	131	70.3%	157	30.8%	157
	EMEA	3,005	4,253	3,967	32.0%	5,050	18.7%	5,050
OTC Pharmaceuticals	Total	8,985	11,578	9,631	7.2%	11,577	(0.0%)	11,577
	Japan	8,180	10,607	9,024	10.3%	10,810	1.9%	10,810
	Asia	627	786	605	(3.6%)	767	(2.5%)	767

From the fiscal year ending March 2026, Hong Kong has been changed from “Asia” to “China.” The calculation of year-on-year change rates also reflects this change in the figures for the fiscal year ended March 2025.

EYLEA products are co-promoted products of Bayer Yakuhin, Ltd. (MAH).

Forecasts in this report are based on currently available information. Actual results may differ materially depending on a number of factors including changes to the business environment and others. Our full-year forecasts are based on our foreign exchange assumptions. Revenue by region shows that of major countries or regions.

(2) Research & Development

As of January 2026

Pipeline Development Status (Clinical Stage)

<Glaucoma and ocular hypertension area>

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
tafluprost / timolol maleate	STN1011101 / DE-111A	Glaucoma / Ocular hypertension	Co-development with AGC	China						Aug-2025
A fixed dose combination drug of a prostaglandin $F_{2\alpha}$ derivative and a beta-adrenergic receptor blocker. Launched in Japan in November 2014. Launched successively in European countries since January 2015. Launched successively in Asian countries since April 2016. Launched in China in August 2025.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
omidenepag isopropyl	STN1011702	Glaucoma/ Ocular hypertension	Co-development with UBE Corporation	China						
A unit dose, preservative free eye drop, EP2 receptor agonist with a new mechanism of action, sold in Japan and Asia. Conducting Phase 3 in China from November 2024.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
sepetaprost	STN1012600 / DE-126	Glaucoma / Ocular hypertension	ONO PHARMACEUTICAL	U.S.						
				Japan						Oct-2025
				Europe	(Exploratory study)					
A bicyclic prostaglandin derivative with a mode of action that is an agonist for FP and EP3 receptors for the treatment of glaucoma and ocular hypertension. Completed an additional Phase 2 in the U.S. in December 2021. Launched in Japan in October 2025. Completed Phase 2 (exploratory study) in Europe.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
latanoprost	STN1013001 / DE-130A (Catioprost)	Glaucoma / Ocular hypertension	Original	Europe						Aug-2024
				Asia					Nov-2024	
An ophthalmic emulsion of a prostaglandin $F_{2\alpha}$ derivative, for the treatment of glaucoma and ocular hypertension. Filed for marketing approval in Asia in November 2024. Launched in European countries including Spain in August 2024.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
netarsudil mesylate	STN1013900 / AR-13324	Glaucoma / Ocular hypertension	Alcon Inc.	Japan					Jul-2025	
				Europe						Feb-2023
				Asia						Nov-2024
A ROCK (Rho-associated kinase) inhibitor. Developed and sold by Alcon Inc. in the U.S.. Filed as a ROCK/NET (norepinephrine transporter) inhibitor for manufacturing and marketing approval in Japan in July 2025. Received marketing approval in Europe and has been launched in Sweden and other countries from February 2023. Successively received marketing approval in Asian countries and launched in South Korea in November 2024.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
netarsudil mesylate / latanoprost	STN1014000 / PG-324	Glaucoma / Ocular hypertension	Alcon Inc.	Europe						Jan-2023
				Asia						Mar-2025
A fixed dose combination drug of a ROCK (Rho-associated kinase) inhibitor and a prostaglandin $F_{2\alpha}$ derivative. Developed and sold by Alcon Inc. in the U.S.. Received marketing approval in Europe and has been launched in Germany and other countries from January 2023. Received marketing approval successively in Asian countries and launched in Singapore in March 2025.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
netarsudil mesylate / latanoprost	STN1014003	Glaucoma / Ocular hypertension	Alcon Inc.	Japan						
A fixed dose combination drug of a ROCK (Rho-associated kinase) inhibitor and a prostaglandin $F_{2\alpha}$ derivative. Developed and sold by Alcon Inc. in the U.S.. Uses a different container from that of STN1014000. Started Phase 3 in Japan in February 2025.										

<Keratoconjunctival disease area including dry eye >

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
ciclosporin	STN1007603 / DE-076C	Vernal keratoconjunctivitis	Original	China						Dec-2025
An ophthalmic emulsion which improves vernal keratoconjunctivitis by immunosuppressive effect. Cationic emulsion technology has enhanced ocular tissue penetration. Launched successively in European countries since October 2018. Launched successively in Asian countries after receiving approval for an indication expansion for *Ikervis* in August 2019. Launched in China in December 2025.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
olodaterol hydrochloride	STN1014100	Dry eye	Boehringer Ingelheim	Japan		(Phase 2b)				
β_2 receptor agonist. Started Phase 2b in Japan in May 2025.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
sirolimus	STN1010904	Fuchs endothelial corneal dystrophy	Joint development with ActualEyes	U.S. France India	(Phase 2a)					
An ophthalmic suspension which treats Fuchs endothelial corneal dystrophy via mTOR inhibition. Conducting Phase 2a in U.S., France and India from May 2022. (*The development code (STN1010904) is due to be assigned to the product when Santen obtains an exclusive license upon completion of Phase 2 clinical trial)										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
sirolimus	STN1010905	Meibomian gland dysfunction	Original	Japan	(Phase 2a)					
An ophthalmic suspension which improves meibomian gland function via mTOR inhibition. Conducting an additional Phase 2a in Japan from June 2024.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
epinastine hydrochloride	STN1011402	Allergic conjunctivitis	Nippon Boehringer Ingelheim	Japan					May-2024	
				China						
				Asia				Dec-2025		
A histamine H_1 receptor antagonist with mediator release inhibitor function, as a treatment for allergic conjunctivitis. Ophthalmic eyelid cream. Launched in Japan in May 2024. Started Phase 3 in China in January 2026. Filed for marketing approval in Asia in December 2025.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
epinastine hydrochloride	STN1011403	Allergic conjunctivitis	Boehringer Ingelheim	China				Mar-2025		
A histamine H_1 receptor antagonist with mediator release inhibitor function, as a treatment for allergic conjunctivitis. High dose formulation to instill twice a day. Filed for marketing approval in China in March 2025.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
nintedanib	STN1014200 / CBT-001	Pterygium	Cloudbreak Pharma Inc.	Japan	(Phase 2b)					
A multi-kinase inhibitor which suppresses angiogenesis and fibrosis. Started Phase 2b in Japan in November 2025.										

< Refractive disorder>

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
atropine sulfate	STN1012700 / DE-127	Myopia	Singapore Health Services, Nanyang Technological University	Japan					Apr-2025	
				China		(Phase 2/3)				
				Asia				July-2025		
Non-selective muscarinic antagonist which reduces the progression of juvenile myopia. Launched in Japan in April 2025. Conducting Phase 2/3 in China from June 2022. Filed for marketing approval in Asia in July 2025.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
atropine sulfate	STN1012701 / SYD-101	Myopia	Sydnexis Inc.	Europe					July-2025	
Non-selective muscarinic antagonist which reduces the progression of juvenile myopia. In Europe, launched in Germany in July 2025.										

< Retinal diseases area >

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
eflimrufusp alfa	STN1014300 / RC28-E	Diabetic macular edema	RemeGen Co., Ltd.	China				Sep-2025		
Dual decoy receptor IgG1 Fc-fusion protein drug simultaneously blocks both VEGF-A and FGF-2. RemeGen Co., Ltd., the licensor, filed for marketing approval in China in September 2025.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
eflimrufusp alfa	STN1014301 / RC28-E	Wet age-related macular degeneration	RemeGen Co., Ltd.	China						
Dual decoy receptor IgG1 Fc-fusion protein drug simultaneously blocks both VEGF-A and FGF-2. RemeGen Co., Ltd., the licensor, is conducting Phase 3 trial in China.										

<Others>

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
oxymetazoline hydrochloride	STN1013800	Ptosis	RVL Pharmaceuticals	Japan					Dec-2025	
				Europe						
				China						
A direct-acting alpha adrenergic receptor agonist. Developed and sold by RVL Pharmaceuticals in the U.S.. Received manufacturing and marketing approval in Japan in December 2025. Conducting Phase 3 in Europe from December 2024. Conducting Phase 3 in China from October 2024.										

Changes from Q2 FY2025 (November 6, 2025)

Dev. Code	Changes
STN1007603 / DE-076C	Launched in China in December 2025.
STN1011402	Started Phase 3 in China in January 2026. Filed for marketing approval in Asia in December 2025.
STN1014200 / CBT-001	Started Phase 2b in Japan in November 2025.
STN1013800	Received manufacturing and marketing approval in Japan in December 2025.

(3) Capital Expenditures, Depreciation and Amortization, Amortization on Intangible Assets Associated with Products, and Research and Development Expenses

Capital expenditures (JPY millions)

	Nine months ended December 31, 2024	Year ended March 31, 2025	Nine months ended December 31, 2025	Year ending March 31, 2026
	Actual			Forecast
Consolidated	5,865	7,545	5,494	9,000

(Note):
Excluding the increase in right-of-use assets

Depreciation and amortization (JPY millions)

	Nine months ended December 31, 2024	Year ended March 31, 2025	Nine months ended December 31, 2025	Year ending March 31, 2026
	Actual			Forecast
Manufacturing cost	2,963	3,967	2,904	4,020
Selling, general and administrative expenses	1,596	2,122	1,877	2,730
R&D expenses	406	543	477	510
Consolidated total	4,965	6,632	5,258	7,260

(Note):
Excluding amortization on intangible assets associated with products, long-term advance expense and right-of-use assets

Amortization on intangible assets associated with products (JPY millions)

	Nine months ended December 31, 2024	Year ended March 31, 2025	Nine months ended December 31, 2025	Year ending March 31, 2026
	Actual			Forecast
Merck products	3,698	4,815	3,322	4,400
Rhopressa/Rocklatan	1,071	1,506	1,379	1,750
PRESERFLO MicroShunt	972	1,296	948	1,230
Ikervis	701	926	567	570
Other	196	267	435	750
Consolidated total	6,638	8,812	6,651	8,700

Research and development expenses (JPY millions)

	Nine months ended December 31, 2024	Year ended March 31, 2025	Nine months ended December 31, 2025	Year ending March 31, 2026
	Actual			Forecast
Consolidated	16,773	24,103	18,372	25,000

(4) FOREX

(JPY)

Exchange rate (yen)	Major currency	Nine months ended December 31, 2024	Fiscal year ended March 31, 2025	Nine months ended December 31, 2025	Fiscal year ending March 31, 2026 (Forecasts)
	USD	152.63	152.70	148.91	145.00
	EUR	164.96	163.57	171.67	160.00
	CNY	21.33	21.29	20.88	20.50

Forecasts in this report are based on currently available information. Actual results may differ materially depending on a number of factors including changes to the business environment and others.